Drugs / LUCAR-G39P
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06295549 | Apr 2024 → Jun 2025 | B-cell non-Hodgkin lymphoma | The First Affiliated Hospital with Nanjing Medical University | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUCAR-G39P | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06295549 ↗ |
| Modality | Cell therapy | “dual-targeted cell preparation” NCT06295549 ↗ |